Whitfield Dianne C. 4

What Happened

• Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals (TARS), had restricted stock units (RSUs) vest and settle on March 15, 2026. The filing shows 23,909 shares were issued upon settlement (reported as an acquisition, code M), and four related disposals totaling 23,909 shares (4,463; 7,248; 7,176; 5,022) reported at $0.00 each. The acquisition and disposals offset, indicating shares were issued on vesting and an equal number were withheld/disposed (commonly to cover taxes). No cash proceeds or market sales were reported.

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (appears timely).
• Reported as derivative conversions/exercise (transaction code M) for RSU settlement.
• Shares acquired on settlement: 23,909 (price N/A for RSU settlement).
• Shares disposed/withheld: 23,909 total (4,463; 7,248; 7,176; 5,022) at $0.00 — reported as derivative disposals (likely tax withholding), no sale proceeds disclosed.
• Shares owned after transaction: not specified in the filing.
• Footnotes: Shares issued pursuant to settlement of vested RSUs (each RSU = right to one share). RSUs originated from grants in 2022–2025 with standard 25% annual vesting schedules (see F3–F6).

Context

• These entries reflect RSU vesting and net settlement/withholding rather than an open-market purchase or sale. The disposals at $0.00 typically represent shares retained by the company to satisfy tax withholding obligations and do not necessarily signal insider sentiment. Purchases would be considered more informative about bullishness; this is a routine compensation-related transaction.